Dr David Millan

  • Affiliate (School of Cancer Sciences)

Publications

List by: Type | Date

Jump to: 2022 | 2021 | 2020 | 2014
Number of items: 6.

2022

Gershenson, D. M. et al. (2022) Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet, 399(10324), pp. 541-553. (doi: 10.1016/S0140-6736(21)02175-9) (PMID:35123694) (PMCID:PMC8819271)

2021

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)

2020

Stevenson, A., Wakeham, K., Pan, J., Kavanagh, K., Millan, D., Bell, S., McLellan, D., Graham, S.V. and Cuschieri, K. (2020) Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours. Journal of Clinical Virology, 129, 104505. (doi: 10.1016/j.jcv.2020.104505) (PMID:32604039)

2014

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi: 10.1097/IGC.0000000000000289)

Lindsay, R., Burton, K., Shanbhag, S., Tolhurst, J., Millan, D. and Siddiqui, N. (2014) Fertility conserving management of early cervical cancer. International Journal of Gynecological Cancer, 24(1), pp. 118-123. (doi: 10.1097/IGC.0000000000000023)

This list was generated on Mon Aug 15 14:25:24 2022 BST.
Jump to: Articles
Number of items: 6.

Articles

Gershenson, D. M. et al. (2022) Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet, 399(10324), pp. 541-553. (doi: 10.1016/S0140-6736(21)02175-9) (PMID:35123694) (PMCID:PMC8819271)

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)

Stevenson, A., Wakeham, K., Pan, J., Kavanagh, K., Millan, D., Bell, S., McLellan, D., Graham, S.V. and Cuschieri, K. (2020) Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours. Journal of Clinical Virology, 129, 104505. (doi: 10.1016/j.jcv.2020.104505) (PMID:32604039)

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi: 10.1097/IGC.0000000000000289)

Lindsay, R., Burton, K., Shanbhag, S., Tolhurst, J., Millan, D. and Siddiqui, N. (2014) Fertility conserving management of early cervical cancer. International Journal of Gynecological Cancer, 24(1), pp. 118-123. (doi: 10.1097/IGC.0000000000000023)

This list was generated on Mon Aug 15 14:25:24 2022 BST.